| Literature DB >> 31480223 |
Maryam Alkandari1, Kath Ryan1, Amelia Hollywood2.
Abstract
Peripheral neuropathy is a neurological disease characterised by pain, numbness, tingling, swelling or muscle weakness due to nerve damage, caused by multiple factors such as trauma, infections and metabolic diseases such as diabetes. In Kuwait 54% of the diabetic population, has peripheral neuropathy. In this exploratory, qualitative study conducted in Kuwait, 25 subjects with peripheral neuropathy took part in one-on-one, semi-structured interviews lasting 45-60 min. Interviews were transcribed, translated into English and coded using NVivo 12. Four individual patient journeys were mapped out in detail, then compared and condensed into a single process map. The remaining 21 interviews were then reviewed to ensure the final map represented all patient journeys. Participants reported similar healthcare pathways for their peripheral neuropathy and faced various difficulties including lack of psychological support, administrative issues (long waiting referral periods, loss of medical documents, shortage of specialists and lack of centralized electronic medical records) and inadequate medical care (shortage of new treatments and deficient follow-ups). Mapping the patient journey in Kuwait showed similar pharmacological treatment to UK guidelines, except that some medicines were unavailable. The map also indicated the need for an integrated referral approach, the use of technology for electronic medical recording and report transmission, alongside education on self-management, coping mechanisms and treatment options for people living with peripheral neuropathy.Entities:
Keywords: Kuwait healthcare; diabetes; patient experiences; peripheral neuropathic pain; process map
Year: 2019 PMID: 31480223 PMCID: PMC6789644 DOI: 10.3390/pharmacy7030127
Source DB: PubMed Journal: Pharmacy (Basel) ISSN: 2226-4787
Characteristics of people living with peripheral neuropathy in Kuwait.
| Characteristics | Observations ( | |
|---|---|---|
| Nationality | Kuwaiti | 20 |
| Non-Kuwaiti | 5 | |
| Sex | Male | 12 |
| Female | 13 | |
| Age (years) | Range | 35–82 |
| Mean (Standard Deviation) | 55 (SD = 10) | |
| Comorbidities | Type 2 Diabetes Mellitus | 16 |
| Hypertension | 10 | |
| Dyslipidaemia | 8 | |
| Duration of peripheral neuropathy (years) | Range | 3–30 |
| Mean (Standard Deviation) | 13.76 (SD = 7.4) |
Figure 1A Process Map of People Living with Peripheral Neuropathy in Kuwait.3.1. Primary care clinic—the journey starts.
Investigational procedures carried out for people living with peripheral neuropathy in Kuwait.
| Centre | Investigational Procedures Performed |
|---|---|
| Primary clinic-general practitioner | Blood routine, random blood sugar, fasting blood sugar and postprandial blood sugar for diabetics |
| General hospital-doctor | Blood routine and HbA1c (glycosylated haemoglobin) |
| General hospital-neurologist | Blood routine, HbA1c and other blood test, advanced neurological investigations: loss of protective Sense, +1 of reflex ankle-vibration- pin prick- gait |
| National hospital-neurology specialist/consultant | Physical examinations, full neurovascular examination, nerve conduction study and foot care diabetic peripheral neuropathy. Investigation and examination: HbA1c and other blood tests |
Treatment options provided for people living with peripheral neuropathy in Kuwait. * The current study showed that people with peripheral neuropathy, who are mainly diabetics, were not using Carbamazepine 200–400 mg tablets or Gabapentin 300–1200 mg tablets as first line medications.
| General pain management | ketoprofen (Fastum 2.5%) Gel | 1 |
| etoricoxib (Arcoxia) 30 mg tablets | 1 | |
| ibuprofen (Ibuprofen) 200–400 mg tablets | 10 | |
| acetaminophen (Acetaminophen) 500 mg tablets | 5 | |
| alpha-lipoic acid (Thiotacid) 600 mg tablets | 2 | |
| vitamin b complex (B complex) 500 mg tablets | 7 | |
| First line treatment * | pregabalin (Lyrica) 75–150 mg tablets | 8 |
| Tricyclic antidepressants (TCAs): Amitriptyline (Tryptizol) 25–150 mg tablets | 1 | |
| Second line treatment | Selective serotonin and norepinephrine reuptake inhibitor (SSNRI): duloxetine (Cymbalta 60–120 mg capsules and Cymbatex 30 mg capsules) | 1 |
| Third line treatment | Opioids: tramadol (Tramol) 50 mg Tablets | 1 |